Related Experiment Videos
Cyanate as an inactivator of complement proteins
Insights
Sodium cyanate inactivates key complement proteins like C3 and C5 in human serum, impacting immune function. This is crucial for sickle-cell disease patients who may already have complement deficiencies.
Area of Science:
- Immunology
- Biochemistry
- Complement System
Background:
- The complement system is vital for innate immunity and host defense.
- Sickle-cell disease patients often exhibit complement deficiencies, increasing infection risk.
- Sodium cyanate is being explored as a potential therapeutic for sickle-cell disease.
Purpose of the Study:
- To investigate the effect of sodium cyanate on complement protein function in human serum.
- To determine the mechanism and extent of complement inactivation by sodium cyanate.
- To assess the implications of cyanate-induced complement inactivation for sickle-cell disease patients.
Main Methods:
- Incubation of normal and sickle-cell patient serum with varying concentrations of sodium cyanate.
- Functional assays to measure the activity of complement components (C3, C5, C6, C7, C8, C9, C3b inactivator).
- Radiolabeling and binding studies with 14C-cyanate, circular dichroism, and electrophoresis to analyze protein modification and structure.
Main Results:
- Sodium cyanate functionally inactivated C3, C5, C6, C7, and C3b inactivator in a dose- and time-dependent manner.
- Inactivation occurred via direct carbamylation, as evidenced by protein binding and lack of structural changes in C3.
- Cyanate-treated C3 retained binding capacity but showed impaired immune adherence and agglutination functions.
Conclusions:
- Sodium cyanate directly inactivates critical components of the complement system.
- This inactivation, particularly of C3, may compromise host defense mechanisms.
- The findings highlight a significant concern for using sodium cyanate in sickle-cell disease patients due to potential exacerbation of immune deficiencies.
Abstract:
Sodium cyanate added to normal human serum or serum from patients with sickle-cell disease resulted in the functional inactivation of C3, C5, C6, C7, and the C3b inactivator, but not C8 and C9. Final concentrations as low as 0.5 mM in serum caused inactivation of 12 to 64% of the C3 after 8 hr at 37 degrees C. The activity of the inactivated C3, C5, and C3b inactivator was not restored by dialysis. Most of the functional activity of C3 in cyanate-treated sera was destroyed by very small quantities of 14C-labeled cyanate that was bound to the protein. C3 inactivation by cyanate occurred in heated sera (50 degrees C, 30 min) and sera treated with EDTA, probably indicating that one mechanism for inactivation was by a direct carbamylation reaction. Both C3 and C5 showed two anodal-migrating forms in two dimensional antigen-antibody crossed electrophoresis in some sera treated with low concentrations of cyanate. Measurements of circular dichroism of highly purified carbamylated C3 showed no detectable changes in structure even though most of the functional activity was destroyed. Purified, inactive C3 that was carbamylated with 14C-labeled cyanate was capable of binding to EAC142, but the resulting EAC1423 was weakly positive for immune adherence and negative for agglutination with anti-C3 antiserum. Unlabeled, cell-bound C3b on EAC142 was not susceptible to cyanate action as shown by no loss in immune adherence and positive agglutination with anti-C3 antiserum. The C3b inactivator was more susceptible to cyanate than C3 in a short time period, whereas both were inactivated after 8 hr. Since cyanate is currently being evaluated as a treatment for sickle-cell disease, the inactivation of C3 by the drug is an important consideration for such patients who are already deficient in C3 dependent heat-labile opsonins that aid in host defense.